US Push to Reshore Generic Drug Manufacturing Faces Steep Hurdles
Trump wants generic drugs made in America, but cheap overseas labor and entrenched global supply chains make that goal difficult to achieve.
President Trump's push to revive domestic generic drug manufacturing runs headlong into economic and logistical realities that have shaped the pharmaceutical industry for decades, with India serving as a stark illustration of why the transition would be neither quick nor cheap.
India has become a dominant force in the global generic drug supply by leveraging low labor costs and deeply integrated supply networks that allow manufacturers there to produce medicines at a fraction of what it would cost in the United States. Those structural advantages did not emerge overnight, and industry analysts warn they cannot be replicated domestically by executive order alone.
Read more Democrats Focus on Billionaires While Missing a Quieter Wealthy Class →
Global supply chains represent a compounding challenge. Raw pharmaceutical ingredients, known as active pharmaceutical ingredients, are sourced across multiple countries, often flowing through China and India before reaching final production facilities. Rebuilding that web of inputs domestically would require massive capital investment, workforce training, and regulatory alignment across a fragmented industry.
The economics of generic drugs further complicate any reshoring effort. Unlike branded pharmaceuticals, generics compete almost entirely on price, leaving razor-thin margins that make high-wage American manufacturing difficult to sustain without subsidies, tariffs, or other policy levers. Any cost increase passed to consumers or insurers could undercut the very affordability that makes generics central to the U.S. healthcare system.
Policymakers face a fundamental tension: the same market forces that made offshore generic production so attractive are the forces that any domestic manufacturing push must overcome. Continue reading at NYT > Business.
